<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03490344</url>
  </required_header>
  <id_info>
    <org_study_id>18-048</org_study_id>
    <nct_id>NCT03490344</nct_id>
  </id_info>
  <brief_title>Short Course Daratumumab in Patients With Multiple Myeloma</brief_title>
  <official_title>Short Course Daratumumab in Minimal Residual Disease (MRD) Positive Myeloma Patients After Induction Therapy With/Without Consolidative High Dose Chemotherapy/Autologous Stem Cell Support</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Scientific Affairs, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety of short course Daratumumab in combination&#xD;
      with lenalidomide and to find out what effects, if any, short course Daratumumab in&#xD;
      combination with lenalidomide has on people and their risk of multiple myeloma. The study is&#xD;
      also designed to test the amount of remaining myeloma cells in your body after treatment with&#xD;
      daratumumab which is known as minimal residual disease (MRD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 3, 2018</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of MRD negativity by the completion of 6 months of daratumumab therapy</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Participants with Multiple Myeloma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with MM with very good partial response (VGPR) or better after induction therapy with/without consolidative HDT/ASCT and MRD positive by bone marrow flow cytometry and MM participants who were previously MRD negative after induction and consolidation and recently (within last 3 months) turned MRD positive by bone marrow flow cytometry will be enrolled.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab</intervention_name>
    <description>Cycles 1 and 2: Daratumumab 16mg/kg weekly per cycle (28 days) as intravenous infusion (total duration: 8 weeks)&#xD;
Cycles 3-6: Daratumumab 16mg/kg once every 2 weeks per cycle (28 days) as intravenous infusion (total duration: 16 weeks)</description>
    <arm_group_label>Participants with Multiple Myeloma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Lenalidomide maintenance therapy to be administered as standard treatment to all participants. This is administered as 5-15 mg daily 21-28/28 day cycle.</description>
    <arm_group_label>Participants with Multiple Myeloma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a diagnosis of Multiple Myeloma who have achieved a VGPR or better&#xD;
             (based on best response) after induction with or without consolidation therapy/ HDT&#xD;
             ASCT&#xD;
&#xD;
          -  MRD positive at screening by flow cytometry&#xD;
&#xD;
          -  Additionally, patients who were previously MRD negative after induction therapy&#xD;
             with/without consolidative HDT/ASCT and have turned MRD positive (by flow cytometry)&#xD;
             based on bone marrow done at screening and do not have any evidence of progressive&#xD;
             disease are eligible&#xD;
&#xD;
          -  Patients must be on standard of care lenalidomide maintenance therapy for at least 6&#xD;
             months at the time of study enrollment&#xD;
&#xD;
          -  Patient can be receiving bisphosphonate therapy per the treating oncologist's&#xD;
             discretion&#xD;
&#xD;
          -  Creatinine clearance ≥45 ml/min using the Cockcroft-Gault method, MDRD, or CKD-EPI&#xD;
             formula. If the calculated CrCl based on Cockcroft-Gault method, MDRD, or CKD-EPI is&#xD;
             &lt;45 mL/min, patient will have a 24 hr urine collection to measure CrCl.&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2&#xD;
&#xD;
          -  Male or female patient who accepts and is able to use recognized effective&#xD;
             contraception (oral contraceptives, IUCD, barrier method of contraception in&#xD;
             conjunction with spermicidal jelly) throughout the study when relevant.&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) ≥1.0 x 10^9/L, hemoglobin ≥8 g/dL, and platelet count&#xD;
             ≥75 x 10^9/L. No transfusion or growth factor support for one week prior to labs.&#xD;
&#xD;
          -  Adequate hepatic function, with bilirubin &lt; 1.5 x the ULN, and AST and ALT &lt; 2.5 x ULN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a diagnosis of MM not achieving a VGPR or better to the most recent&#xD;
             therapy.&#xD;
&#xD;
          -  Patients with a diagnosis of MM who are MRD Negative by flow cytometry&#xD;
&#xD;
          -  Patients must not have measurable disease at the time of enrollment. Measurable&#xD;
             disease is defined as follows&#xD;
&#xD;
               -  Serum monoclonal protein &gt; 0.5 gm/dL&#xD;
&#xD;
               -  Urine monoclonal protein &gt; 200 mg/24 hours&#xD;
&#xD;
               -  Involved serum free light chain &gt; 10 mg/dL&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  Uncontrolled hypertension or diabetes&#xD;
&#xD;
          -  Has significant cardiovascular disease with NYHA Class III or IV symptoms, or&#xD;
             hypertrophic cardiomegaly, or restrictive cardiomegaly, or myocardial infarction&#xD;
             within 3 months prior to enrollment, or unstable angina, or unstable arrhythmia&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including but not limited to active infection or&#xD;
             psychiatric illness/social situations that would compromise compliance of study&#xD;
             requirements&#xD;
&#xD;
          -  Active infection requiring treatment within two weeks prior to first dose&#xD;
&#xD;
          -  Contraindication to any concomitant medication, including antivirals, anticoagulation&#xD;
             prophylaxis, tumor lysis prophylaxis, or hydration given prior to therapy&#xD;
&#xD;
          -  Major surgery within 1 month prior to enrollment&#xD;
&#xD;
          -  Previous therapy with daratumumab or other anti-CD38 monoclonal antibodies&#xD;
&#xD;
          -  History of other malignancy (apart from basal cell carcinoma of the skin, or in situ&#xD;
             cervix carcinoma) except if the patient has been free of symptoms and without active&#xD;
             therapy during at least 5 years&#xD;
&#xD;
          -  Active hepatitis B or C infection&#xD;
&#xD;
          -  Subject is:&#xD;
&#xD;
               -  seropositive for human immunodeficiency virus (HIV)&#xD;
&#xD;
               -  seropositive for hepatitis B (defined by a positive test for hepatitis B surface&#xD;
                  antigen [HBsAg]). Subjects with resolved infection (ie, subjects who are HBsAg&#xD;
                  negative but positive for antibodies to hepatitis B core antigen [anti-HBc]&#xD;
                  and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened&#xD;
                  using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus&#xD;
                  (HBV) DNA levels. Those who are PCR positive will be excluded. EXCEPTION:&#xD;
                  Subjects with serologic findings suggestive of HBV vaccination (anti-HBs&#xD;
                  positivity as the only serologic marker) AND a known history of prior HBV&#xD;
                  vaccination, do not need to be tested for HBV DNA by PCR. seropositive for&#xD;
                  hepatitis C (except in the setting of a sustained virologic response [SVR],&#xD;
                  defined as aviremia at least 12 weeks after completion of antiviral therapy).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sham Mailankody, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sham Mailankody, MBBS</last_name>
    <phone>212-639-2131</phone>
    <email>mailanks@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexander Lesokhin, MD</last_name>
    <phone>212-639-3069</phone>
    <email>lesokhia@mskcc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sham Mailankody, MBBS</last_name>
      <phone>212-639-2131</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sham Mailankody, MBBS</last_name>
      <phone>212-639-2131</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sham Mailankody, MBBS</last_name>
      <phone>212-639-2131</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sham Mailankody, MBBS</last_name>
      <phone>212-639-2131</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sham Mailankody, MBBS</last_name>
      <phone>212-639-2131</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sham Mailankody, MBBS</last_name>
      <phone>212-639-2131</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sham Mailankody, MBBS</last_name>
      <phone>212-639-2131</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 30, 2018</study_first_submitted>
  <study_first_submitted_qc>April 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2018</study_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bony plasmacytoma</keyword>
  <keyword>extramedullary plasmacytoma</keyword>
  <keyword>Daratumumab</keyword>
  <keyword>lenalidomide</keyword>
  <keyword>Memorial Sloan Kettering Cancer Center</keyword>
  <keyword>18-048</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

